产品名称
Anti-Synuclein α Antibody, Chemicon®, from rabbit
biological source
rabbit
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
rat, human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable (paraffin)
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... SNCA(6622)
Physical form
ImmunoAffinity Purified
Affinity Purified immunoglobulin. Lyophilized, no preservatives. Reconstitute with 20 μL of sterile distilled water. Centrifuge to remove any residue.
Analysis Note
Control
Brain tissue
Brain tissue
Application
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
This Anti-Synuclein Antibody, α is validated for use in IH(P), WB for the detection of Synuclein.
Western blot: 1:1000-1:2000
Immunohistochemistry: 1:1000-1:2000 on paraffin sections, 1:4000-1:12,000 on frozen sections..
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 1:1000-1:2000 on paraffin sections, 1:4000-1:12,000 on frozen sections..
Optimal working dilutions must be determined by end user.
Biochem/physiol Actions
Recognizes Alpha-synuclein. The immunizing peptide was chosen to reduce cross-reactivity of AB5038 with beta-synuclein to a minimum. Immunohistochemical and Western blot analysis of human brain indicates a high level of specificity.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
14-19 kDa
alpha -Synuclein is a small (140-amino acid) cytoplasmic protein of unclear function that is enriched in presynaptic terminals and is the precursor protein of a nonamyloid beta component of senile plaques in Alzeheimer′s Disease (AD). alpha -Synuclein is located predominantly in the presynaptic nerve terminals in the brain but is also found in low concentrations in all tissues except liver. Recent studies have shown that abnormal aggregation and accumulation of synaptic proteins, including alpha-Synuclein might be associated with plaque formation in AD and seems to be a major component of Lewy bodies in dementia with Lewy bodies (DLB). It has also been identified in the Glial Cytoplasmic Inclusions (GCIs) found in Multiple System Atrophy (MSA).
Immunogen
Human alpha-synuclein residues 111-131 coupled to KLH. The peptide sequence is N-GILEDMPVDPDNEAYEMPSEEC-C. This peptide is available for use in blocking studies (Cat. No. AG239).
Other Notes
Replaces: 04-1053
Preparation Note
Maintain at -20 in undiluted aliquots for up to 12 months after date of receipt. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles. Glycerol (1:1) can be added for additional stability.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Juan C Vizcarra et al.
Free neuropathology, 4 (2023-06-22)
The collection of post-mortem brain tissue has been a core function of the Alzheimer Disease Research Center's (ADRCs) network located within the United States since its inception. Individual brain banks and centers follow detailed protocols to record, store, and manage
Christopher Gibbons et al.
Neurology, 100(15), e1529-e1539 (2023-01-20)
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder caused by the abnormal accumulation of α-synuclein in the nervous system. Clinical features include autonomic and motor dysfunction, which overlap with those of Parkinson disease (PD), particularly at early disease stages.
Michael Helwig et al.
Brain : a journal of neurology, 139(Pt 3), 856-870 (2016-01-01)
Aggregation and neuron-to-neuron transmission are attributes of α-synuclein relevant to its pathogenetic role in human synucleinopathies such as Parkinson's disease. Intraparenchymal injections of fibrillar α-synuclein trigger widespread propagation of amyloidogenic protein species via mechanisms that require expression of endogenous α-synuclein
Raffaella Rusconi et al.
Aging cell, 17(2) (2018-02-01)
Increased expression of α-synuclein can initiate its long-distance brain transfer, representing a potential mechanism for pathology spreading in age-related synucleinopathies, such as Parkinson's disease. In this study, the effects of overexpression-induced α-synuclein transfer were assessed over a 1-year period after
Dominique Bétemps et al.
Acta neuropathologica communications, 2, 29-29 (2014-03-15)
The accumulation of misfolded proteins appears as a fundamental pathogenic process in human neurodegenerative diseases. In the case of synucleinopathies such as Parkinson's disease (PD) or dementia with Lewy bodies (DLB), the intraneuronal deposition of aggregated alpha-synuclein (αS) is a
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持